HK1206246A1 - Use of high dose laquinimod for treating multiple sclerosis - Google Patents
Use of high dose laquinimod for treating multiple sclerosis Download PDFInfo
- Publication number
- HK1206246A1 HK1206246A1 HK15106789.5A HK15106789A HK1206246A1 HK 1206246 A1 HK1206246 A1 HK 1206246A1 HK 15106789 A HK15106789 A HK 15106789A HK 1206246 A1 HK1206246 A1 HK 1206246A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treating
- human patient
- multiple sclerosis
- human
- presenting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641389P | 2012-05-02 | 2012-05-02 | |
| US61/641,389 | 2012-05-02 | ||
| PCT/US2013/039090 WO2013166166A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1206246A1 true HK1206246A1 (en) | 2016-01-08 |
Family
ID=49514859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106789.5A HK1206246A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130303569A1 (https=) |
| EP (1) | EP2844255A4 (https=) |
| JP (2) | JP2015515985A (https=) |
| KR (1) | KR20150013658A (https=) |
| CN (2) | CN105832733A (https=) |
| AR (1) | AR090885A1 (https=) |
| AU (1) | AU2013256352A1 (https=) |
| BR (1) | BR112014027010A2 (https=) |
| CA (1) | CA2870684A1 (https=) |
| CL (1) | CL2014002935A1 (https=) |
| EA (1) | EA201492010A1 (https=) |
| HK (1) | HK1206246A1 (https=) |
| IL (1) | IL235337A0 (https=) |
| MX (1) | MX2014013039A (https=) |
| PE (1) | PE20150161A1 (https=) |
| PH (1) | PH12014502447A1 (https=) |
| SG (1) | SG11201406594UA (https=) |
| TW (2) | TW201347762A (https=) |
| UY (1) | UY34775A (https=) |
| WO (1) | WO2013166166A1 (https=) |
| ZA (1) | ZA201408820B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2851525A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| BR112015007782A2 (pt) * | 2012-10-12 | 2017-07-04 | Teva Pharma | laquinimod para reduzir danos talâmicos na esclerose múltipla |
| EP2916915A4 (en) | 2012-11-07 | 2016-06-22 | Teva Pharma | LAQUINIMOD AMINE SALTS |
| BR112015019564A2 (pt) * | 2013-02-15 | 2017-07-18 | Teva Pharma | tratamento de esclerose múltipla com laquinimod |
| US20160046582A1 (en) | 2013-03-14 | 2016-02-18 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| ES3009670T3 (en) * | 2018-07-20 | 2025-03-31 | Merck Patent Gmbh | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| US20080118553A1 (en) * | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| JP2012530701A (ja) * | 2009-06-19 | 2012-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症のラキニモドでの治療 |
| EP2523668A1 (en) * | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| CA2851525A1 (en) * | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| BR112015019564A2 (pt) * | 2013-02-15 | 2017-07-18 | Teva Pharma | tratamento de esclerose múltipla com laquinimod |
-
2013
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en not_active Ceased
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Withdrawn
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AR090885A1 (es) | 2014-12-10 |
| KR20150013658A (ko) | 2015-02-05 |
| CN105832733A (zh) | 2016-08-10 |
| US20150265592A1 (en) | 2015-09-24 |
| US20130303569A1 (en) | 2013-11-14 |
| CL2014002935A1 (es) | 2015-03-06 |
| AU2013256352A1 (en) | 2014-11-27 |
| ZA201408820B (en) | 2016-06-29 |
| EP2844255A4 (en) | 2015-10-14 |
| PE20150161A1 (es) | 2015-02-22 |
| JP2015515985A (ja) | 2015-06-04 |
| EA201492010A1 (ru) | 2015-06-30 |
| PH12014502447A1 (en) | 2015-01-12 |
| JP2017222691A (ja) | 2017-12-21 |
| MX2014013039A (es) | 2015-02-04 |
| EP2844255A1 (en) | 2015-03-11 |
| BR112014027010A2 (pt) | 2017-06-27 |
| IL235337A0 (en) | 2014-12-31 |
| CN104284663A (zh) | 2015-01-14 |
| TW201804997A (zh) | 2018-02-16 |
| TW201347762A (zh) | 2013-12-01 |
| WO2013166166A1 (en) | 2013-11-07 |
| UY34775A (es) | 2013-11-29 |
| SG11201406594UA (en) | 2014-11-27 |
| US20160000775A1 (en) | 2016-01-07 |
| CA2870684A1 (en) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2011013902A (es) | Tratamiento de esclerosis multiple con laquinimod. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
| JP2016505050A5 (https=) | ||
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| JP2015515971A5 (https=) | ||
| BR112012020415A2 (pt) | composição farmacêutica para a prevenção ou tratamento da osteoartrite | |
| WO2012125871A3 (en) | Aconitine compounds, compositions, uses, and preparation thereof | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| NZ599227A (en) | Therapeutic agent for chronic pain |